The majority of patients with DiGeorge syndrome (DGS), velocardiofacial syndrome (VCFS), conotruncal anomaly face syndrome (CTAFS) and some individuals with familial or sporadic conotruncal cardiac defects have hemizygous deletions of chromosome 22. Most patients with these disorders share a common large deletion, spanning >1.5 Mb within 22q11.21-q11.23. Recently, the smallest region of deletion overlap has been narrowed to a 250 kb area, the minimal DGS critical region (MDGCR), which includes the locus D22S75 (N25). We have isolated and characterized a novel, highly conserved gene, DGSI, within the MDGCR. DGSI has 10 exons and nine introns encompassing 1702 bp of cDNA sequence and 11 kb of genomic DNA. The encoded protein has 476 amino acids with a predicted mol. wt of 52.6 kDa. The intron-exon boundaries have been analyzed and conform to the consensus GT/AG motif. The corresponding murine Dgsi has been isolated and localized to proximal mouse chromosome 16. The mouse gene contains the same number of exons and introns, and the predicted protein has 479 amino acids with 93.2% identity to that of the human DGSI gene. By database searching, both genes have significant homology to a Caenorhabditis elegans hypothetical protein, F42H10.7. Further, mutation analysis has been performed in 16 patients, who have no detectable 22q11.2 deletion and some of the characteristic clinical features of DGS/ VCFS. We have detected eight sequence variants in DGSI. These occurred in the 5′-untranslated region, the coding region and the intronic regions adjacent to the intron-exon boundaries of the gene. Seven of the eight variants were also present in normal controls or unaffected family members, suggesting they may not be of etiologic significance.
INTRODUCTION
A group of developmental disorders, including DiGeorge syndrome (DGS), velocardiofacial syndrome (VCFS), conotruncal anomaly face syndrome (CTAFS) and some familial or sporadic conotruncal cardiac defects, have been associated with microdeletion of 22q11.2 (1) (2) (3) (4) (5) . These diseases encompass a wide spectrum of clinical manifestations, and the phenotypes of individual patients do not correlate with the extent of this deletion (1, 6, 7) . Molecular and cytogenetic studies of patients with the 22q11 deletion indicate that most patients share a large deletion, which spans >1.5 Mb within 22q11.21-q11.23 (1, 3, (8) (9) (10) . We and others have utilized breakpoint mapping data from selected patients with DGS/VCFS to define the proximal and the distal boundaries of the smallest region of deletion overlap (7) (8) (9) 11, 12) . This region has been narrowed further to 250 kb (minimal DGS critical region, MDGCR) by the recent analysis of an unbalanced 15;22 translocation in a VCFS patient (12, 13) . It has been proposed that the gene(s) within the MDGCR are strong candidates for involvement in the pathogenesis of the 22q11 deletion disorders. Four genes, LAN/DGCR2/IDD (9, 14, 15) , the human citrate transport protein gene (CTP) (16) , the human clathrin heavy chain-like gene (CLTCL) (17) (18) (19) and DGCR5 (20) are within the MDGCR and have been described previously. However, there is as of yet no convincing evidence to support the hypothesis that any of these genes play a significant role in the development of DGS/VCFS. Thus, it is reasonable to postulate that additional genes in this region may be involved in the etiology of DGS/VCFS. Further, although 22q11.2 deletions have been demonstrated in the majority of patients with DGS, VCFS and CTAFS, a minority of patients with some of the characteristic features of these disorders do not have a detectable deletion by fluorescence in situ hybridization (FISH) (10) . Mutation analysis *To whom correspondence should be addressed The full-length cDNA was assembled from this series of expressed fragments including a 5′ RACE and a 3′ RACE fragment, two cDNAs (c4A10 and c4G11) isolated by cDNA selection and two cDNA clones (SM-2 and SM-3) isolated from a skeletal muscle cDNA library. Sequence analysis demonstrated that SM-2 was a chimeric clone with the aldolase A gene.
of a candidate gene(s) for DGS/VCFS in these non-deleted patients may assist in detection of small deletions, insertions, duplications or point mutations and thus help to define the role of the various genes in the etiology of the disease phenotype.
We have identified several novel transcription units within the MDGCR, including the gene DGSI (17) . In this report, we characterize the structure and genomic organization of this gene. We have also isolated and characterized the corresponding murine cDNA (Dgsi), which maps to proximal mouse chromosome 16, the region with conserved linkage to the human MDGCR. Comparison of the amino acid sequences between human and mouse DGSI indicates that this gene is highly conserved. We have determined the exon-intron boundaries of both human and mouse DGSI. In addition, heteroduplex and sequence analysis of DGSI in a small group of non-deleted DGS/VCFS individuals has revealed four polymorphisms and four rare sequence variants.
RESULTS

Characterization of the human DGSI cDNA
The DGSI transcript (accession no. L77566) maps to the central portion of the MDGCR (Fig. 1A) . On Northern blots containing mRNA from 23 adult and four fetal tissues, two different sized mRNAs were detected ( Fig. 2A ) using the probe c4A10 (Fig.  1D) . One is 1.7 kb and is expressed in all adult and fetal tissues tested. The other transcript is 5.2 kb in size and is strongly expressed in adult skeletal muscle and heart. After a longer exposure, a weak 5.2 kb band was also seen in the four fetal tissues tested (brain, lung, liver and kidney) by Northern analysis (data not shown), suggesting the possibility of alternative splicing. A transcript representing the 1.7 kb signal seen on Northern blots could be assembled from clones isolated by cDNA selection and 3′ and 5′ RACE products (Fig. 1D) . The transcript is 1702 bp in length, excluding the 85 bp poly(A) tail. Efforts to identify cDNAs representing the larger transcript were made which included screening a cDNA library. Since the 5.2 kb transcript is highly expressed in adult skeletal muscle, the probe c4A10 was used to screen a human skeletal muscle cDNA library. Two positive clones (SM-2 and SM-3) (Fig. 1D) were isolated, but sequence analysis demonstrated that neither of these cDNAs represents an alternatively processed transcript of DGSI. This raises a question as to whether the 5.2 kb transcript actually represents an alternative form of DGSI or a related expressed sequence located elsewhere in the genome. To examine this possibility, Southern hybridization to a complete monochromosomal hybrid panel was performed with the same probe (c4A10) that was used for the Northern blot analysis. A single 5.5 kb EcoRI band was seen in total human DNA (Fig. 2B) . The only somatic cell hybrid which gave the same size band was the one containing human chromosome 22 (GM10888) (Fig. 2B) , suggesting that DGSI is a single-copy gene. Additional experiments to characterize the larger transcript further will be required. Sequence analysis of the 1702 bp DGSI transcript demonstrates that there is an AUG codon at position 10 which shows good agreement with Kozak's consensus sequence (A/GCGAUGG). However, the 5′ RACE product extended the 5′ end of DGSI only 9 bp upstream of the start codon. To determine the bona fide transcription initiation site, primer extension was performed using adult skeletal muscle mRNA and an antisense oligonucleotide complementary to position 104-127 bp of DGSI cDNA sequence (see Materials and Methods). Extension products of 196 and 301 bp with equal intensity were observed (Fig. 3) , indicating that the transcription start site of the DGSI gene is heterogeneous. The longest open reading frame (ORF) is 1428 bp and the predicted protein consists of 476 amino acids with a mol. wt of 52.6 kDa. Approximately 40% of the amino acids are hydrophobic. Proline-rich regions are seen in both the N-terminal (amino acids 1-20, 98-146) and C-terminal (308-346) ends which contain 20, 21 and 21% proline, respectively. The most C-terminal region (421-471) is proline and serine/threonine rich, containing 17% proline and 32% Ser/Thr. In addition, the coding region contains several short homopolymeric runs of proline, alanine and glutamate. Although the function of these domains in DGSI are unknown, proline-rich and serine/threonine-rich regions have been identified as transcription activation domains (21, 22) .
BLAST searches of the GenBank databases using the deduced amino acid sequence of this gene showed a match to a Caenorhabditis elegans hypothetical protein, F42H10.7, whose function is unknown (accession no. P34420). Overall there is 53% similarity and 30% identity with three highly conserved regions (70-80% similarity) observed between the human and C.elegans predicted proteins (Fig. 4A) . The first conserved region was in the N terminus of DGSI (amino acids 37-102) where limited homology was also found to the C-terminal half of Drosophila expanded protein (accession no. L14768) with 53% similarity and 32% identity over 66 amino acids. Further, three casein kinase-2 (CK-2) phosphorylation sites were recognized in the two remaining conserved regions (amino acids 147-190, 312-332), suggesting that the DGSI-encoded protein may be a member of a group of CK-2-mediated phosphorylated proteins. 
Isolation and characterization of the mouse Dgsi gene
On a zoo-blot containing nine eukaryotic species, c4A10 identified strong positive signals in human, monkey, rat, mouse and dog. Somewhat weaker signals were observed in cow and rabbit (data not shown), suggesting that DGSI is conserved. Recently, a 150 kb genomic DNA contig encompassing the region of mouse chromosome 16 which is syntenic to the human MDGCR has been constructed (Galili et al., in press). A 38 kb cosmid from this contig has been sequenced completely (accession no. U70231) and sequence analysis demonstrates that there is a high degree of identity between DGSI and the mouse genomic DNA sequence. Using primers designed from the conserved region in the mouse genomic sequence (see Materials and Methods), a 1437 bp RT-PCR product was generated from 9-day mouse embryo and embryonic heart mRNA. RACE experiments were carried out using primers derived from the ends of the RT-PCR product (see Materials and Methods). Sequence analysis of the RT-PCR and 5′ and 3′ RACE products allowed the assembly of 1732 bp of mouse Dgsi cDNA sequence, including the 5′ methionine start codon and a 3′ polyadenylation signal ATTAAA followed by a poly(A) tail (accession no. GSDB:S:1118295). The predicted protein has 479 amino acids, and comparison between the amino acid sequence of human and mouse DGSI revealed 96.8% similarity and 93.2% identity overall (Fig. 4B) , indicating that this gene is highly conserved in evolution. Further, Dgsi shows 52.5% similarity and 30.6% identity to the C.elegans hypothetical protein, F42H10.7 using BLASTP.
Gene structure and genomic organization of the human and mouse DGSI
The structure of the human and mouse DGSI genes were determined by comparison between the cDNA sequence and the corresponding genomic sequence (accession no L77570 and U70231, respectively). The 5′ end of the human DGSI gene is 31 kb upstream of the CTP gene (16) , and its 3′ end is 12 kb downstream of the LAN/DGCR2/IDD gene (9, 14, 15) . Human DGSI consists of 10 exons and nine introns spanning 1.7 kb of cDNA and 11 kb of genomic DNA (Fig. 1) . The sizes of the exons range from 96 (exon 3) to 170 bp (exon 4), except the last exon which is the largest (541 bp), containing 280 bp of coding sequence and 261 bp of 3′-untranslated region (UTR). The intron length varies between 92 (intron 2) and 2513 bp (intron 3). Similarly, the mouse Dgsi gene also contains 10 exons and nine introns encompassing 1.7 kb of cDNA sequence and 9.6 kb of genomic DNA. The first exon of mouse Dgsi contains 144 bp of coding region and a short 5′-UTR. The last exon of mouse Dgsi contains 280 bp of coding sequence and 280 bp of 3′-UTR. Although the 3′-UTR of the mouse Dgsi gene is 19 bp larger than that of the human DGSI gene, the polyadenylation signal, ATTAAA, is conserved and located 18 bp upstream of the poly(A) tail of both transcripts. All introns, except intron 7, of the mouse Dgsi gene are smaller than those of the human DGSI gene. The exon-intron boundaries of both genes were identified, and the donor and acceptor splice site at each exon-intron junction conform to the consensus (Table 1) . It is interesting to note that a variation in splicing is found at the boundary of intron 3 and exon 4. As indicated in Table 1 , the mouse selects the first ag as the acceptor site, while the human selects the second ag, resulting in an insertion of CAG in the mouse Dgsi cDNA sequence. This insertion was detected in expressed sequences derived from the whole mouse embryo and the heart. All other exon-intron boundaries occur in the same position with respect to the coding sequence.
The genomic DNA surrounding the first exon of human and mouse DGSI has been analyzed and compared. There is 64% identity over 635 bp in intron 1 between both DGSI genes. Despite the fact that the nucleotide sequence of the 5′ upstream region is somewhat less conserved, and two SpI elements and two CACCC boxes seen in the human DGSI gene are not found in mouse Dgsi, the two regions share certain features. Both lack TATA consensus in the immediate upstream region. Further, a putative CAAT box and a possible binding site for ATF/CREB (TGACGTCA) (23) were observed in the 5′ upstream region of both genes (Fig. 5) .
Mutation analysis
Mutation analysis was performed on a small group of patients who did not have a detectable 22q11.2 deletion by FISH analysis, but have two or more of the clinical features consistent with a diagnosis of DGS (four cases) or VCFS (10 cases). In addition, two 'non-deleted' siblings with truncus arteriosus (TA) were studied, since it has been reported that 33% of all patients with TA have DGS (24) . Screening was first performed on these 16 patients, four family members and 31 normal controls. The 5′ upstream region (primers DGS-I.1, Table 2 ) and the first exon (primers DGS-I.2, Table 2) were assessed both by heteroduplex analysis and by direct sequencing. Since similar results were obtained with the two methods, we used heteroduplex analysis for the subsequent screening experiments. Genomic fragments flanking each exon and the 5′ upstream region of DGSI were amplified using the primers listed in Table  2 . PCR fragments that gave altered heteroduplex patterns were sequenced. In this study, eight single-base substitutions were identified ( Table 3) . Four of these changes (base 93, 1006 and 1268 in the coding region and base 75 in intron 9 ) were observed in both patients and at least one of the 31 normal controls, indicating that they represent polymorphisms. The remaining four single-base changes were found only in three affected patients (patients 1, 11 and 14) but not in the controls. To determine if they represent rare polymorphisms, 72 additional normal controls were analyzed using allele-specific oligonucleotide (ASO) hybridization (25) . All four variants are contained within the PCR product generated using the primers DGS-I.2. Two SpI elements and two CACCC boxes, which are found in the human DGSI but not in the mouse Dgsi, are underlined. In the putative promoter region two sequence variants were found. They are shown by stars.
Thus, the labeled mismatched ASO probes (ASO-M) could be pooled and hybridized to Southern blots of this PCR-generated fragment. DGS-I.2 PCR products were generated from patients, family members and 103 normal controls. In addition to the expected positive signal from patients 1, 11 and 14, the PCR product from the parents of patient 11 and one normal control also hybridized to the pooled ASO-M probes.
Sequence analysis of these PCR fragments revealed four nucleotide changes. At position -43 a C→T substitution was found in patient 14. This patient has cleft palate, tetralogy of Fallot, facial dysmorphia and short stature. However, this substitution was also found in one of 103 normal controls (C32), and most probably represents a rare sequence variant. Two changes, one at -2 (C→G) and the other at 92 (C→T), were observed in patient 11. Patient 11 has an affected sibling (patient 9) who was also included in the study. These sisters (patient 9 and patient 11) have clinical features seen in the 22q11 deletion syndrome, including congenital heart defects (ASD, VSD, PDA), speech delay, mild facial dysmorphia, short stature and learning difficulties. The nucleotide substitution in patient 11 occurs at -2 within the Kozak's consensus region (GcGATGG→GgGATGG). This change is also seen in her unaffected father. The second substitution, at position 92, is in a CpG dinucleotide and changes an alanine to a valine in the predicted protein sequence. The change at position 92 is also observed in the patient's unaffected mother. However, neither of the two single-base changes seen in patient 11 are observed in her affected sister (patient 9). These results suggest that the changes in this family represent rare sequence variants (they were not found in 103 unaffected controls). Further, sequence analysis showed an additional base change, adjacent to the C→T change at position 92, in patient 9 and her mother. The most common base at position 93 is a G, but patient 9 and her mother are heterozygous (G/A) at this position (Table 3 ). The mutational analysis of DGSI and subsequent genotype analysis with additional markers in the DGCR indicates that the affected siblings do not share a common parental chromosome 22. This makes it unlikely that the genes responsible for their clinical features are located on chromosome 22. Thus, this family has been excluded from further mutational analysis of candidate gene(s).
The remaining single-base change, a transition of G→A at nucleotide -65, was found in patient 1 (Fig. 6) but not observed in any of the 103 normal controls (i.e. 206 chromosomes). Patient 1 had interrupted aortic arch type A, thymic aplasia and mild facial dysmorphia. The patient died at 6 weeks and no cell line is available for further studies. Parental DNA was not available to determine the origin of this nucleotide transition.
DISCUSSION
We have isolated and characterized a novel gene, DGSI, within the MDGCR which, based on its map position, is a potential candidate gene for DGS/VCFS or related disorders. DGSI is hemizygously deleted in the vast majority of patients with DGS/VCFS. Despite the absence of homology between DGSI and other genes or proteins with known function, it is highly conserved in eukaryotic species. Comparison of the deduced amino acid sequence reveals 96.8 and 53% similarity between the human and mouse DGSI, and the human DGSI and the C.elegans predicted protein (P34420), respectively. At the N-terminal conserved region, there is a 66 amino acid stretch with a high degree of similarity to the Drosophila expanded protein (ex). Included in the region of similarity between ex and DGSI are two regions which are rich in proline and glutamic acid. The function of the region of ex with similarity to DGSI is unknown. However, ex is an essential gene in Drosophila, necessary for proper growth control of imaginal discs. Some ex mutants display phenotypes affecting head, thorax, legs and wings in heterozygotes (26) . Further evidence of a role for DGSI in development comes from RT-PCR experiments which demonstrate that Dgsi is expressed in early mouse development. A transcript was detected at 9 days in mouse whole embryo and heart. Additional in situ hybridization experiments on mouse embryo sections will be required to determine the precise location of Dgsi expression in the early mouse embryo.
In our study, mutational analysis of all 10 exons and the 5′ upstream region of DGSI was performed on patients with features of DGS/VCFS but no detectable deletion of 22q11. The rationale for this strategy is based on the premise that if loss of a single gene is responsible for features of the 22q11 deletion syndrome then there should be patients who, instead of deletions, have mutations within the causative gene. Failure to find patients with mutations could indicate either that the gene under study is not the correct gene or that haploinsufficiency of multiple genes is required for expression of the phenotype. A further complication to this type of analysis is that DGS/VCFS is known to be etiologically heterogeneous. Exposure to teratogens (27) , maternal diabetes (28) and rearrangements of other chromosomal regions, including 4q (29) , 10p13 (30) and 17p13 (31) , have been seen in association with patients diagnosed with DGS. Nonetheless, mutational analysis of candidate genes is a necessary step to distinguish between these possibilities.
Sixteen non-deleted patients were selected for mutational analysis. Eight nucleotide changes, all single-base substitutions, were found in seven non-deleted patients. Five were observed in both patients and normal controls, indicating that these are normal variants. Three base pair changes were found only in two affected patients (patients 1 and 11). Two changes, at -2 (C→G) and 92 (C→T) were only observed in patient 11 and her unaffected parents, suggesting that these are rare variants. Further, detailed genotyping of this family excluded 22q11 as a candidate region.
A third nucleotide change was found in patient 1. This is a G→A transition found in the promoter region of DGSI. It is 65 bp upstream from the translation start codon, 7 bp upstream of a putative SpI binding site and 28 bp downstream of the putative CAAT box. The guanosine at position -65 is conserved in the mouse Dgsi sequence. It is possible that this single-base substitution in the promoter region could influence transcription. Such an example has been reported for the apolipoprotein A-I gene, where an A→G transition 78 bp upstream from the transcription initiation site has been associated with decreased promoter activity in vitro and apoA-I production in vivo (32) . Another example is a T→C substitution at nt -39 in the promoter region of the lipoprotein lipase gene. As a result of this single nucleotide change, the transcriptional activity of the mutant promoter was <15% of wild-type (33) . However, in our study, the significance of this G→A change seen in patient 1 is unclear, because similar nucleotide changes have yet to be found in other non-deleted DGS/VCFS patients. Further, this change does not occur within any recognizable cis-acting element. Additional studies to determine the transcriptional consequences of this change will be required.
In summary, we propose that DGSI remains a candidate gene for DGS/VCFS syndrome and related abnormalities. Firstly, this gene maps within the MDGCR and is hemizygous in the vast majority of patients with the 22q11 deletion. Secondly, DGSI is highly conserved in eukaryotic species and expressed during early mouse development. Finally, a rare sequence variant which could represent a possible mutation has been detected in one DGS patient. The wide phenotypic variability in patients with the 22q11 deletion has led to the suggestion that multiple genes from the deleted region may be responsible for the wide range of clinical features. DGSI is located in a region from which several novel transcripts are produced, creating a small gene cluster (17) . It is possible that more than one of the genes in this gene-rich region may be associated with the etiology of DGS/VCFS. Additional experiments, such as functional analysis of DGSI and knockouts of this gene in a murine model, will be essential to clarify the possible developmental role of DGSI in producing the phenotype of the 22q11 deletion syndrome. 
MATERIALS AND METHODS
Patient materials
Genomic DNA was available from 16 patients referred to our laboratory with either a diagnosis of DGS/VCFS (14 cases) or an isolated conotruncal cardiac malformation (two affected siblings). Clinical summaries were provided on 13 of the 14 DGS/VCFS patients by a referring geneticist and/or immunologist. All 13 had two or more of the major clinical features seen in these disorders including congenital heart defect, absent thymus or a history of frequent infections, palatal abnormalities and/or speech difficulties, facial dysmorphia and a history of learning disabilities or developmental delay. Clinical information was not available on one patient (P3) referred with the diagnosis of VCFS. Twelve of the 14 DGS/VCFS cases were sporadic; patients 9 and 11 were siblings with the diagnosis of DGS. The remaining two patients were siblings (P16 and P17) with TA, a diagnosis frequently seen in DGS. These siblings have no other features of DGS or VCFS.
Screening of cDNA library by hybridization
A 5′ stretch-λgt10 human adult skeletal muscle library (Clontech) was screened using c4A10 as probe. The library was plated at a density of ∼300 000 p.f.u. per 150 mm plate on the Escherichia coli host strain Y1090. Filter hybridization was performed according the protocol provided by the manufacturer.
RT-PCR
cDNA was synthesized in a 50 µl reaction using 100 ng of poly(A) RNA extracted from various tissues. The RNA was heated with random and oligo(dT) primers for 5 min at 65_C and cooled to room temperature for 10 min. Reverse transcription was performed at 37_C for 1 h after adding 5 µl of 10× RT buffer (Stratagene), 20 U of RNase inhibitor (Stratagene), 2 µl of 0.1 M dNTPs and 50 U of MMLV reverse transcriptase. The cDNA mixture then was heated for 5 min at 90_C. For PCR amplification, 2 µl of cDNA was used per 50 µl reaction. The primers for mouse Dgsi are: GGACTTCA-GACAGTTATCCAGAGAGACTTC (F) and ACTAGATATTTG-TGGCTCCTGGAATAATCA (R).
RACE-PCR
Marathon-ReadyT mouse skeletal muscle cDNA (Clontech) was used in PCR with an anchor primer provided by the manufacturer and a gene-specific antisense primer, 5′-GAAGTCTCTCTGGA-TAACTGTCTGAAGTCC-3′ for 5′ RACE and a sense primer, 5′-GACGCAAAGCTTCAGACTTCTTTTAG-3′ for 3′ RACE. PCR was performed in 50 µl reactions using 1× PCR buffer (Clontech): 40 mM Tricine-KOH, 15 mM KOAc, 3.5 mM Mg(OAc) 2 , 75 mg/ml bovine serum albumin and 0.25 U of KlenTaq-1 DNA polymerase (Clontech). PCR conditions were: a 1 min denaturation step at 94_C followed by 30 cycles of, denaturation at 94_C for 30 s, annealing and extension at 68_C for 3 min, and lastly a 3 min extension at 68_C. The PCR reactions were performed in Perkin Elmer 9600 thermal cyclers. PCR products were analyzed by gel electrophoresis using 1-1.5% agarose.
DNA sequencing
Double-stranded plasmid DNA was prepared and purified using the Wizard Mini Prep DNA Purification System (Promega) and sequenced from both ends on an ABI 373A sequencer using the universal forward and reverse M13 fluorescent primers. PCR products were purified using the QIA quick gel extraction kit (Qiagen) and directly sequenced using the primers specific for PCR amplification. Cosmid sequencing was performed using a doublestranded random shotgun approach described elsewhere (34) .
Primer extension
Primer extension analysis was performed using a modified protocol (35) . An antisense primer, 5′-ATACTCTT-CCTCGTCCAGGACCC-3′, was end-labeled with [γ-32 P]ATP and 10 6 c.p.m. of labeled primer was mixed with 2 µg of adult skeletal poly(A) RNA in a volume of 20 µl. The mixture was precipitated, redissolved in 40 µl of hybridization buffer (0.3 M KCl, 10 mM Tris-HCl at pH 7.6, 0.5 mM EDTA) and then heat-denatured at 75_C for 5 min. The hybridization was carried out overnight at 37_C and terminated by precipitation. The pellet was redissolved in reverse transcriptase buffer containing 1.0 U/µl of RNase inhibitor and 50 U of MMLV reverse transcriptase (Stratagene) and incubated for 1 h at 37_C. The reaction was terminated by addition of 1 µl of 0.5 M EDTA (pH 8.0). The RNA portion of the hybrid was removed by digestion with 1 µl of DNase-free pancreatic RNase (5 µg/ml) at 37_C for 30 min. The extended products were phenol extracted, ethanol precipitated, heated at 65_C for 5 min, and analyzed by 8% denaturing polyacrylamide gel electrophoresis followed by autoradiography.
Heteroduplex analysis
Heteroduplex analysis was performed using a protocol described elsewhere (36) . Primers flanking each exon (except for exon 2 and exon 3) and the 5′ upstream region of DGSI were designed from intronic sequence, 100 bp upstream or downstream of the exon-intron boundaries as listed in Table 2 . Genomic fragments from all patients and controls examined were amplified using these primers and their sizes range from 193 to 478 bp. PCR products with different sizes were mixed, denatured at 98_C for 5 min and incubated at 65_C for 1 h to induce heteroduplex formation. Approximately 10 µl of each sample subsequently was electrophoresed though a standard sequencing gel containing 10% polyacrylamide (99:1 w/w acrylamide:bis-acrolylpiperazine, Fluka), 10% ethylene glycol, 15% formamide, 0.2% ammonium persulfate in 0.5× TTE buffer for 16-18 h at 400-600 V.
Allele-specific oligonucleotide (ASO) probe hybridization
The allele-specific oligonucleotides were designed based on the single base changes of DGSI detected by heteroduplex analysis and direct sequencing and have the same length (17 bases). The mismatched oligonucleotides (ASO-M) are: G2A, 5′-CAAAT-GATGCAGTCCCG -3′; C24T, 5′-TCCACCTTGTGACGC-GC-3′; C65G, 5′-GATAGGGATGGAGACGC-3′; C159T, 5′-GGCTGTGACGAGCAAGC-3′. The discriminating single base mismatch between the oligonucleotide probe and the DGSI sequence is located 6-7 bases from the 5′ end of the oligonucleotide probe, and is indicated by bold letters. Thirty µM of each ASO probe were end-labeled with [γ-32 P]ATP in 1× T4
polynucleotide kinase buffer containing 20 mM dithiothreitol (DTT), 1 U of T4 polynucleotide kinase for 1 h at 37_C. All four labeled ASO-M probes were pooled and hybridized to Southern blots containing the genomic PCR products, amplified from normal individuals using the primers listed in Table 2 , in TMAC hybridization buffer (3 M tetramethylammonium chloride, 0.6% SDS, 1 mM EDTA, 10 mM Na 3 PO 4 pH 6.8, 5× Denhardt solution, 40 µg/ml yeast RNA) overnight at 56_C.
